Data Integrity (DI) is part of the mission to ensure the safety, efficacy, and quality of products produced by the pharmaceutical industry, the global regulators (e.g., the US FDA, EMA, etc.) expect that all data submitted by manufacturers to obtain market approval is both reliable and accurate. Regulators consider the integrity of data, from the moment it is generated to the end of its life cycle, to be a critical component of ensuring that only high-quality and safe drugs are manufactured. Data integrity requires that all data be attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, and available.
Guidance Documents
Advanced Manufacturing (1)
+Artificial Intelligence (1)
+Commissioning & Qualification (1)
+Data Integrity (16)
+GAMP® (15)
+Knowledge Management (1)
+Manufacturing Operations (1)
+Pharma 4.0™ (1)
+Regulatory (1)
+Validation (10)
+Community Discussions
Community Discussions
Mar 28, 2025
Information Systems
Regulatory
Advanced Manufacturing
Artificial Intelligence
Mar 20, 2025
Data Integrity
Jan 26, 2025
Data Integrity
Dec 11, 2024
Data Integrity
Nov 27, 2024
Data Integrity
Webinars
Upcoming
On-Demand
iSpeak Blog Posts
Pharmaceutical Engineering Magazine Articles
Videos
White Papers
January / February 2025
GAMP® is indispensable for safeguarding the safety, quality, and compliance of pharmaceutical…
January / February 2024
Stakeholders across industries are becoming accustomed to using information technology (IT) systems…

Pharmaceutical Job Board
Professional Development Training
A GAMP® Guide to Computerized Systems Compliance
+GAMP® Data Integrity 21 CFR Part 11, 2-Day Training Course
+GAMP® Data Integrity 21 CFR Part 11, 3-Day Training Course
+Featured Conferences
